Quo Vadis, CDI Drugs?

There are only 3 CDI drugs in wider clinical use: vancomycin, metronidazole, and fidaxomicin. They are from totally different classes and have almost nothing in common except for proven efficacy in C. difficile infection (CDI). Like vancomycin, the entire group of glycopeptide drugs seems to have good activity against C. Continue reading Quo Vadis, CDI Drugs?

Overcoming Antimicrobial Resistance – A European Report Recommends Deja-Vu Action

Sometimes one comes across a particularly well-written policy document which summarizes the status quo of antimicrobial resistance by connecting and synthesizing data from all kinds of sources into a coherent framework. The 2015 OECD Report on Antimicrobial Resistance in G7 Countries and Beyond: Economic Issues, Policies and Options for Action Continue reading Overcoming Antimicrobial Resistance – A European Report Recommends Deja-Vu Action

Recent Sepsis Literature

SIRS, sepsis, severe sepsis, septic shock is a continuum, a crescendo of signs and symptoms associated with an infection uncontrolled by host responses. An avalanche or cascade of seemingly unstoppable events occurs often in a matter of hours which has defied causal intervention but for which symptomatic treatment has improved Continue reading Recent Sepsis Literature